Navigation Links
Promising strategy for treatment of lung cancer
Date:3/29/2010

A research team at the Sahlgrenska Academy at the University of Gothenburg, Sweden, has shown in a study that two closely related enzymes could be targets for the treatment of lung cancer. The discovery was made when the researchers blocked the production of the two enzymes in transgenic mice. This resulted in inhibition of cell growth, fewer tumours and greater survival among the mice.

The article is being published in the journal Proceedings of the National Academy of Sciences (PNAS). With many types of cancer, the growth and spread of tumours is stimulated by Ras and Rho proteins. For these proteins to function, they need to be modified by the closely related enzymes FT and GGT. A number of pharmaceutical companies have therefore developed substances that reduce the activity of these two enzymes with the aim of inhibiting the function of Ras and Rho proteins and so slowing the development of the disease.

However, treatment with various substances to block these two enzymes has often been non-specific, and their efficacy has varied widely. This has made it difficult for researchers to assess the true potential of these enzymes as targets for medicines.

"We therefore developed genetic strategies in mice, known as transgenic mice, to switch off the genes coding for FT and GGT, enabling us to investigate whether a complete blockade of FT or GGT can inhibit the development of lung cancer, and whether this has side-effects in the lungs," explains researcher Anna-Karin Sjgren, who led the study together with Meng Liu, both from the Department of Clinical and Molecular Medicine.

In their study, the researchers used transgenic mice which produce a mutated Ras protein that causes lung cancer. First, production of FT or GGT in these mice's lungs was stopped by switching off the relevant genes.

"When we turned off the FT gene, the mice developed fewer lung tumours and lived longer," says Meng Liu. "At cellular level, the blockade of FT meant that the tumour cells were no longer able to divide. When we blocked the production of GGT, we saw the same effects: inhibition of cell growth, fewer lung tumours and improved survival."

In experiments where both genes were switched off at the same time, the number of lung tumours dropped sharply and the mice lived much longer. This means that the absence of these two enzymes does not have any obvious side-effects in the lungs, and that lung tumour cells seem to be more sensitive to the treatment than normal lung cells.

"Our findings show that FT and GGT are promising targets for the treatment of lung cancer," the researchers explain. "The next step in our research is to find out whether blocking these enzymes can have side-effects in other tissues."


'/>"/>

Contact: Anna-Karin Sjgren
anna-karin.sjogren@wlab.gu.se
46-031-342-4723
University of Gothenburg
Source:Eurekalert

Related medicine news :

1. SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients
2. New smoking cessation therapy proves promising
3. Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
4. Sytropin HGH Shows Promising Anti-Aging Results
5. New strategy produces promising advance in cancer vaccines
6. Promising therapy for relapsing multibple sclerosis
7. First blinded study of venous insufficiency prevalence in MS shows promising results
8. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
9. Promising new neuroimaging techniques for early detection of Alzheimers disease
10. LSUHSC research yields promising stroke treatment
11. Promising New Results On The Added Safety Of Using SmokeStik Electronic Cigarettes In The Bid To Quit Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate ... about the benefits of making new water infrastructure a number one priority. “As we ... we expect water infrastructure to become a top priority of our new political change ...
(Date:1/23/2017)... ... 2017 , ... Moisture measurement is a necessary process step ... to success. Selecting an inappropriate measurement method can cause costly errors, and poor ... equipment. Rare or expensive substances are wasted and production may even be stopped ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the Foundation ... the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities ... These resources have been developed for use by nutrition educators and influencers ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to ... the rest of the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of ... like Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, velvety body ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Laboratory Testing Market By Type of Test (Tumor, Clinical Chemistry, ... By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast ... ... destination for healthcare services, market segments, especially clinical lab testing, ...
(Date:1/21/2017)... Research and Markets has announced the addition ... Technology, Route Of Administration, End User - Forecast to 2025" ... ... at a CAGR of around 7.8% over the next decade to ... report analyzes the global markets for Advanced Drug Delivery across all ...
(Date:1/20/2017)... Stock-Callers.com today evaluates the following Drug Manufacturers equities: ... A/S (NYSE: NVO ), Sucampo Pharmaceuticals Inc. (NASDAQ: ... PTX ). These stocks belong to the Healthcare ... finishing near its session lows. As per a NASDAQ report, ... of health care companies in the S&P 500 also were ...
Breaking Medicine Technology: